The point in drug development where a project moves from the clinical to the commercial stage often brings unforeseen challenges that may cause delays in bringing products to market. In this blog post, James S. Drob, Director of Manufacturing Operations, and Judy Cohen, VP of Quality Assurance at the CDMO Division of LLS Health, discuss how drug developers can mitigate capacity issues.

Click here to read the full blog Bridging Clinical and Commercial Drug Product Manufacturing – Outsourcing Advice from a CDMO from Lubrizol Life Science.

Drug shortages, especially for sterile injectables, have been a pressing issue for several years. While pharmaceutical CDMOs have invested in additional manufacturing capacity, market estimates still predict that demand for aseptic manufacturing services will outpace supply in the next two years.

Drug developers report difficulty finding CDMOs with both clinical and commercial manufacturing expertise to help them get to market. In addition, events of the last 12 months have seen COVID-19 vaccines and treatments prioritized by larger pharma companies and their manufacturing partners. This has further reduced available production capacity to commercialize new therapies.

Click here to learn more about our available aseptic manufacturing capacity and schedule a call with an expert from Lubrizol Life Science.